AP2A1 and Alzheimer disease: Of the other CME proteins we evaluated (Supplementary Figures S1, S2), DNM2 (Aidaralieva et al., 2008; Kamagata et al., 2009), AP2A1 (Yao et al., 2000), CLTA (Nakamura et al., 1994), and PICALM (Ando et al., 2013, 2016; Alsaqati et al., 2023) have been shown to exhibit various protein, RNA, or localization changes associated with AD.